Abstract
In Japan, primary lung cancer has been the leading cause of cancer death since 1998, and is still increasing both in prevalence and mortality. In 2006, the number of deaths due to primary lung cancer was approximately 63,000, including 46,000 males and 17,000 females in Japan. Despite the progress of both radiotherapy and chemotherapy, surgical resection remains the first choice of treatment for locally limited (stage I to IIIA) non-small cell lung cancer (NSCLC). Although the surgical results for NSCLC have improved, it is mostly attributed to improvements in diagnostic techniques and early detection of the disease. In fact, the prognosis of patients with locally advanced stages (II or IIIA) is still not satisfactory, even if a complete resection can be performed. According to the current Japanese registry database, the 5-year-survival rate after complete resection is 83.3 % for IA disease, 66.4 % for IB, 60.1 % for IIA, 47.2 % for IIB, and 32.8 % for IIIA [1]. In order to improve the surgical results, both efficient postoperative surveillance and adjuvant chemotherapy are necessary (Fig. 14.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005;50:227–34.
Yano T, Hara N, Ichinose Y, et al. Local recurrence after complete resection for non-small-cell carcinoma of the lung: significance of local control by radiation treatment. J Thorac Cardiovasc Surg. 1994;107:8–12.
Yano T, Yokoyama H, Inoue T, et al. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg. 1994;108:680–3.
Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615–23.
The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350: 351–60.
Winton T, Livingston R, Johnson D, et al. Vinorelbine plus Cisplatin vs. observation in resected non-small-cell-lung cancer. N Engl J Med. 2005;352(25):2589–97.
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association. [ANITA]): A randomized controlled trial. Lancet Oncol. 2006;7:719–27.
Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–21.
Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939–43.
Yano T, Miura N, Takenaka T, et al. Never-smoking non-small cell lung cancer as a separate entity—the clinico-pathologic features and survival. Cancer. 2008;113:1012–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Yano, T., Maehara, Y. (2013). Lung Carcinoma Surveillance Counterpoint: Japan. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_14
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_14
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)